Project/Area Number |
18K07002
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 49020:Human pathology-related
|
Research Institution | Kanazawa Medical University |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 肺扁平上皮癌 / 細胞膜スフィンゴ脂質 / 上皮間葉移行 / sphingosin kinase 1 / 肺胞腔内進展 / 浸潤・転移 / S1P receptor 1-5 / EMT / 気腔内進展 / 肺実質肺胞腔内進展 / 肺癌 / 扁平上皮癌 / Sphinogosin kinase-1 / 細胞膜リン脂質 / SpK-1 / S1PR-1, 2, 3, 5 |
Outline of Final Research Achievements |
To establish a novel therapeutic strategy against invasion and metastasis of squamous cell carcinoma (SCC) of the lung, we investigated expression of sphingosine kinase (SK) 1 and its receptors (SIPR 1-5), which had been reported to show novel functions relating to the progression of cancer, and found the followings: 1. Overexpression of SK1 was demonstrated in squamous cell carcinoma tissue by western; 2. IHC study localized the expression of SK1 in the invasion front of SCC, showing association with the expression of molecules related to epithelial mesenchymal transition (EMT) and to invasion and metastasis; 3. Spreading through air space region showed reduction of SK1 as well as EMT- and invasion-related molecules; 4. The expression of SK1 as well as its receptors showed no correlation with prognosis of patients with SCC.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究は、肺腺癌と比べ分子標的治療の開発が停滞している肺扁平上皮癌・小細胞癌に対する浸潤・転移の新たな制御法の確立に向けた、細胞膜の主要構成分子である細胞膜活性脂質 sphingolipidの新規機能に着目した基礎的研究である。がん死の首座を占める肺癌の進展制御のための基礎データの集積が本研究の社会的意義である。
|